Revance Therapeutics Announces Closing of Public Offering of Common Stock
NEWARK, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the closing of its underwritten public offering of 3,737,500 shares of its common stock at a price to the public of $36.00 per share, which includes …